- Home
- CARM vs PHIO Comparison
CARM vs PHIO Comparison
Compare CARM & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CARM
- PHIO
- Stock Information
- Founded
- CARM 2016
- PHIO 2011
- Country
- CARM United States
- PHIO United States
- Employees
- CARM N/A
- PHIO N/A
- Industry
- CARM Biotechnology: Pharmaceutical Preparations
- PHIO Biotechnology: Pharmaceutical Preparations
- Sector
- CARM Health Care
- PHIO Health Care
- Exchange
- CARM Nasdaq
- PHIO Nasdaq
- Market Cap
- CARM 12.2M
- PHIO 12.1M
- IPO Year
- CARM N/A
- PHIO N/A
- Fundamental
- Price
- CARM $0.37
- PHIO $2.18
- Analyst Decision
- CARM Hold
- PHIO Strong Buy
- Analyst Count
- CARM 5
- PHIO 3
- Target Price
- CARM $0.90
- PHIO $10.67
- AVG Volume (30 Days)
- CARM 25.7M
- PHIO 148.3K
- Earning Date
- CARM 11-06-2025
- PHIO 08-14-2025
- Dividend Yield
- CARM N/A
- PHIO N/A
- EPS Growth
- CARM N/A
- PHIO N/A
- EPS
- CARM N/A
- PHIO N/A
- Revenue
- CARM $10,767,000.00
- PHIO N/A
- Revenue This Year
- CARM N/A
- PHIO N/A
- Revenue Next Year
- CARM N/A
- PHIO N/A
- P/E Ratio
- CARM N/A
- PHIO N/A
- Revenue Growth
- CARM N/A
- PHIO N/A
- 52 Week Low
- CARM $0.14
- PHIO $0.97
- 52 Week High
- CARM $1.27
- PHIO $9.79
- Technical
- Relative Strength Index (RSI)
- CARM 55.76
- PHIO 49.39
- Support Level
- CARM $0.34
- PHIO $1.96
- Resistance Level
- CARM $0.44
- PHIO $2.57
- Average True Range (ATR)
- CARM 0.05
- PHIO 0.13
- MACD
- CARM 0.01
- PHIO 0.04
- Stochastic Oscillator
- CARM 47.28
- PHIO 36.07
About CARM Carisma Therapeutics Inc.
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.
About PHIO Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.